PAREA Part of our Year in Review series PAREA’s Tadeusz Hawrot provides a dispatch from the European Union, which is increasingly engaging in discussions surrounding the medical potential of psychedelics.As Hawrot describes, there are multiple in-roads for psychedelics-related discussions at the EU level as regulators and politicians revise a host of strategies and positions in an attempt to…


Previous articleAIMS v. DEA: Advocating for Open Access to Psilocybin Assisted Therapy
Next articleAlgernon NeuroScience Initiates Traumatic Brain Injury Research Program With DMT; Appoints Global TBI Expert as Advisor